The lawsuit, spearheaded by Levi & Korsinsky, LLP, alleges that Embecta management maintained an overly optimistic outlook for its pen needle segment even as the company suffered significant competitive erosion at a single major customer. According to the complaint, the firm failed to disclose that patients were migrating to competitors at this account, a trend that disproportionately impacted revenue because these customers were not covered by preferred payer plans. The complaint further contends that management obscured broader retail channel weakness, where patients increasingly shifted toward lower-cost purchasing options that excluded Embecta products.

These combined headwinds culminated in a $75 million guidance cut, with pen needle revenue accounting for $53 million of the shortfall. While executives described the pen needle business as incredibly resolute at a January 2026 industry conference and reaffirmed full-year guidance a month later, the lawsuit claims these assertions were at odds with the internal reality of market volume softness. Investors seeking to participate in the recovery effort are encouraged to reach out to Joseph E. Levi at (212) 363-7500 or via email to evaluate their potential claims.